Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 3Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Pancreatic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Urinary Bladder Neoplasms 1Stomach Neoplasms 1Rectal Neoplasms 1Ovarian Neoplasms 1Liver Neoplasms 1Colonic Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

Fluorouracil 25Oxaliplatin 24Irinotecan 24Leucovorin 23Bevacizumab 23Capecitabine 18Cetuximab 15Radiotherapy 6Gene Expression Profiling 5regorafenib 4Immunohistochemistry 4Gemcitabine 4Folfox protocol 4Colonoscopy 4Cisplatin 4Celecoxib 4Amplified Fragment Length Polymorphism Analysis 4Reverse Transcriptase Polymerase Chain Reaction 3Receptor Protein-Tyrosine Kinases 3Polymerase Chain Reaction 3Nivolumab 3Mitomycin 3Doxorubicin 3Cyclophosphamide 3Cholecalciferol 3Biopsy 3Aspirin 3sargramostim 2pembrolizumab 2ixabepilone 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Colonic Neoplasms × veliparib × Clear all
NCT01233505 2014-04-02

Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors

National Cancer Institute (NCI)

Phase 1 Terminated
16 enrolled
BreastGastrointestinalGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Colonic Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡